We evaluated the clinical significance of serum carnitine concentrations in determining the severity of impaired myocardial fatty acid metabolism in idiopathic hypertrophic cardiomyopathy (HCM). We studied 56 asymptomatic or mildly symptomatic patients with HCM. Serum levels of free carnitine and acylcarnitine were measured by the enzymic cycling method. Myocardial scintigraphy with 123 I-labelled 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) was performed, and the images were analysed quantitatively and semi-quantitatively. Serum free carnitine levels were significantly higher in HCM patients than in normal subjects (52.5p9.5 and 42.3p5.5 nmol/ml respectively ; P 0.0001). On the other hand, serum acylcarnitine levels and acyl/free carnitine ratios were lower in HCM patients than in normal subjects (10.2p4.0 nmol/ml and 0.19p0.08, compared with 13.2p3.9 nmol/ml and 0.32p0.11 respectively ; P 0.0001). Clinical characteristics were not significantly different between the patients showing high and normal free carnitine levels, although female patients with high free carnitine levels were few (P l 0.02). Both quantitative and semi-quantitative analyses revealed that the severity of decreased myocardial BMIPP uptake was significantly correlated with serum free carnitine levels (quantitative analysis : r l k0.422, P 0.0012 ; semi-quantitative analysis : r l 0.633, P 0.0001). In the presence of reduced carnitine uptake into the myocardium in HCM, there may also be reduced transport of acylcarnitines out of the myocardium into the plasma. Although inborn errors of fatty acid metabolism and carnitine deficiencies are reported to provoke secondary HCM and are associated with low serum carnitine concentrations, this study has revealed that the levels of carnitine are, in contrast, increased in idiopathic HCM. Moreover, serum carnitine concentrations are a sensitive indicator of the severity of impaired myocardial fatty acid metabolism even in asymptomatic patients with HCM.
INTRODUCTION
Approximately 70 % of myocardial energy requirements are derived from the β-oxidation of non-esterified fatty acids at rest under normal aerobic conditions, while carbohydrates provide the majority of the remaining 30 % of energy production [1, 2] . Long-chain fatty acids are the major substrate for β-oxidation in the myocardium. Non-esterified fatty acids bind to albumin in the bloodstream and are transported to the myocyte via long-chain-fatty-acid-binding protein located in the plasma membrane. Once fatty acids are taken up into the cytoplasm, they bind to heart-type fatty-acid-binding proteins and are activated by long-chain acyl-CoA synthetase [3] . Acyl-CoA is then transferred into the mitochondria via carnitine, carnitine palmitoyltransferase I, carnitine :acylcarnitine translocase, and carnitine palmitoyltransferase II. In the mitochondria, long-chain acylCoA is metabolized by the β-oxidation enzyme system. Carnitine is thus an essential substance that transports long-chain fatty acids into mitochondria, where β-oxidation takes place. Carnitine also modulates the intramitochondrial CoA\acyl-CoA ratio. In the absence of carnitine, β-oxidation ceases, glycogen is depleted, triacylglycerols accumulate, and organ dysfunction results [4] . On the other hand, medium-and short-chain fatty acids are transported directly into mitochondria without any association with carnitine. Medium-and short-chain acyl-CoA synthetases are localized in the mitochondrial matrix. This explains why the oxidation of medium-and short-chain fatty acids is carnitine-independent [5] . The serum level of free carnitine is fairly constant under a variety of conditions [6] . Fatty acid metabolism is thus a significant factor in the pathophysiology of heart diseases.
Single-photon emission computed tomography with "#$I-labelled 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) is an important tool for exploring myocardial fatty acid metabolism. Application of this method in patients with hypertrophic cardiomyopathy (HCM) has revealed reduced BMIPP uptake, chiefly in the hypertrophied myocardium, which is independent of myocardial perfusion [7] . Moreover, a decrease in myocardial BMIPP uptake is considered to be the most sensitive indicator of metabolic abnormalities in HCM, and the degree of decreased BMIPP uptake relates to mortality [8, 9] . The plasma free carnitine concentration is reported to be elevated in patients with congestive heart failure and some kinds of cardiomyopathies, and is associated with poor prognosis [10, 11] , but this has not been fully investigated in idiopathic HCM. Therefore the aim of our study is to assess the clinical significance of serum carnitine levels and to elucidate the relationship between serum carnitine concentration and impairment of myocardial fatty acid metabolism in asymptomatic or mildly symptomatic patients with HCM.
MATERIALS AND METHODS

Subjects
We examined 56 patients with idiopathic HCM (42 men, 14 women ; mean age 56p12 years, range 17-73 years). HCM subgroups were classified as follows : 36 patients with hypertrophic non-obstructive cardiomyopathy (HNCM), seven with hypertrophic obstructive cardiomyopathy (HOCM), and 13 with apical hypertrophic cardiomyopathy (APH). Twelve patients had a family history of HCM. The diagnosis of HCM was based on clinical findings, i.e. echocardiographic demonstration of a hypertrophied, non-dilated left ventricle in the absence of other cardiac or systemic diseases known to cause left ventricular hypertrophy [12, 13] . For our study, only asymptomatic or mildly symptomatic patients (40 patients in New York Heart Association functional class I and 16 in class II) were selected. Patients who had coronary artery disease, congestive heart failure, hypertension, diabetes mellitus or hepatorenal dysfunctions were excluded from the study, because such conditions affect myocardial metabolism and the kinetics of BMIPP, and carnitine is mainly synthesized in the liver and excreted in the urine [10, [14] [15] [16] [17] .
The age-matched control group consisted of 80 normal healthy volunteers (40 men and 40 women ; mean age 54p13 years) who were receiving no medication. All patients and volunteers signed informed consent forms before the study, and the study protocol was approved by the Research Council of our institution.
Determination of serum carnitine concentrations
A 10-ml blood sample was drawn from the antecubital vein of each patient at rest under fasting conditions. Blood samples were centrifuged at 3000 rev.\min at 3 mC for 10 min, and serum samples (4 ml) were stored at k70 mC until assayed. The serum concentration of free carnitine and acylcarnitine was measured by the new enzymic cycling method using NADH, thio-NAD + and carnitine dehydrogenase, as this is a highly sensitive and specific procedure [18, 19] . Enzymes and assay kits for the measurement of total and free carnitine levels were purchased from Kainos Laboratories Co. (Tokyo, Japan).
Incubations were carried out at 37 mC for 3 min in a 10 mm pathlength cuvette, and contained 1 ml of 100 mmol\l Tris\HCl buffer (pH 9.5), 5 mmol\l thio-NAD + , 0.2 mmol\l NADH and 100 k-units\l carnitine dehydrogenase (where 1 unit is defined as the amount of enzyme producing 1 µmol of NADH\min at 37 mC). The rate of thio-NADH production, which is proportional to the amount of L-carnitine, was measured by determining absorbance at 415 nm between 1 and 6 min after the addition of 50 µl of serum specimen or L-carnitine standard solution.
For the determination of total carnitine, 1 k-unit\l acylcarnitine hydrolase was added to the above reagent, as acylcarnitine is hydrolysed to L-carnitine by this enzyme. The acylcarnitine level was calculated as the difference between total carnitine and free L-carnitine concentrations. The concentration of L-carnitine was calculated by comparison with the rate obtained using a 50 µmol\l L-carnitine standard solution. We used a Model UV-250 spectrometer (Shimadzu Seisakusho Co., Kyoto, Japan) and a Cobas-Fara analyser (Roche Co., Nutley, NJ, U.S.A.).
Determination of serum non-esterified fatty acid concentrations
Serum non-esterified fatty acids were analysed by a highperformance chemiluminescent detection method [20] . Serum samples (25 µl 
BMIPP scintigraphy
A dose of 111 MBq of BMIPP (Nihon Medi-Physics Co., Nishinomiya, Japan) was administered intravenously at rest under fasting conditions. Data acquisition for singlephoton emission computed tomography was performed 15 min after injection using a rotating digital scintillation camera (Gamma-camera 901A ; Toshiba Co., Tokyo, Japan) equipped with a collimator. A total of 30 projection images (40 s per frame) were acquired over 180 m from the left posterior oblique 45 m to the right anterior oblique 45 m. The images were reconstructed using a Shepp-Logan filter without correction for attenuation. BMIPP scintigraphy was also performed in 20 people (11 men and 9 women) out of 80 normal healthy volunteers. BMIPP imaging of normal subjects and HCM patients is shown in Figure 1 .
Analysis of BMIPP imaging
BMIPP imaging was analysed quantitatively and semiquantitatively as reported previously [21] . For quan-
Figure 1 BMIPP imaging of normal subjects and HCM patients
SA, short axis ; VLA, vertical long axis. Decreased myocardial uptake is not seen in any segment of the myocardium in normal subjects. However, myocardial BMIPP uptake is prominent in the anterior and posterior junctions of the hypertrophied ventricular septum in HNCM and HOCM patients, and is marked in the left ventricular apex in APH patients.
titative analysis, we calculated the heart\mediastinum uptake ratio from the average scintillation counts. Regions of interest were assigned in the heart and mediastinum on the anterior planar image, and the average scintillation counts in each segment were calculated. For semi-quantitative analysis, the left-ventricular tomograms were divided into 17 segments (Figure 2 ). The short-axis slices were separated into eight segments at the basal and midventricular levels. Vertical long-axis slices were used to evaluate the apical portion of one segment. Each segment was graded visually using a score between 0 and 3 (0, normal ; 1, mildly reduced uptake ; 2, moderately reduced uptake ; 3, markedly reduced uptake\absent activity) in a blinded manner by two experienced nuclear cardiologists. Differences of opinion were resolved by consensus. The sum of each score was defined as the total defect score, reflecting the severity of impaired myocardial fatty acid metabolism.
Echocardiographic study
The echocardiographic study consisted of M-mode, twodimensional and Doppler blood flow measurements with a Hewlett-Packard ultrasound system (Sonos 2500). The BMIPP tomograms were divided into 17 segments : 1 and 9, anteroseptal ; 2 and 10, superoseptal ; 3 and 11, inferoseptal ; 4 and 12, septoinferior ; 5 and 13, lateroinferior ; 6 and 14, inferolateral ; 7 and 15, superolateral ; 8 and 16, anterolateral ; 17, apical.
distributions of hypertrophy, wall thickness, cavity size and wall motion were evaluated from multiple windows [22] . The morphology of the left-ventricular apex was assessed from the apical view for the diagnosis of APH. We also determined the presence or absence of complete end-systolic cavity obliteration at the papillary muscle level in the short-axis view for the diagnosis of HOCM.
Cardiac catheterization
Cardiac catheterization was performed in all the HCM patients by the percutaneous Seldinger technique. Baseline ventricular pressure was evaluated using an end-hole water-filled catheter before cine-angiography. A diagnosis of HOCM was established when a patient had a pressure gradient above 20 mmHg in the left-ventricular outflow tract without provocation. Left ventriculography was then performed in the right anterior oblique projection. Selective coronary angiograms were obtained in multiple projections.
Statistical analysis
Data are expressed as meanspS.D. An unpaired t test or Chi-square test for independence was used to analyse differences between variables. One-way analysis of variance with subsequent Scheffe! 's multiple-range tests was used to compare the data among the three subtypes of HCM. Correlations between continuous variable data were determined by linear-regression analysis. Statistical significance was defined as P 0.05.
RESULTS
Clinical data for HCM patients are summarized in Table 1 .
Serum levels of free carnitine and acylcarnitine, and of non-esterified fatty acids, in patients with HCM Table 2 shows the serum concentrations of free carnitine and acylcarnitine and of non-esterified fatty acids in normal subjects and in patients with HCM. Free carnitine levels in HCM patients significantly exceeded those in normal subjects (52.5p9.5 and 42.3p5.5 nmol\ml respectively ; P 0.0001), but demonstrated no statistically significant differences among the HCM subtypes. Acylcarnitine concentrations in HCM patients were significantly lower than those of normal subjects (10.1p4.0 and 13.2p3.9 nmol\ml respectively ; P 0.0001), although again there were no significant differences among the HCM subtypes. Acylcarnitine\ free carnitine ratios in HCM patients were significantly lower than those of normal subjects (0.19p0.08 and 0.32p0.11 respectively ; P 0.0001). Levels of nonesterified fatty acids, however, showed no statistically significant differences among normal subjects or any HCM subtype groups.
Relationship between carnitine levels and analysis of BMIPP imaging
We investigated the relationship between serum carnitine levels and quantitative or semi-quantitative analysis of BMIPP imaging for identification of impaired myocardial Significance of differences : *P 0.05, **P 0.005, ***P 0.0005, ****P 0.0001 compared with normal subjects.
Subtypes of HCM
Normal subjects (n l 80) HCM (n l 56) HNCM (n l 36) HOCM (n l 7) APH (n l 13)
Free carnitine (nmol/ml) 42.3p5.5 52.5p9.5**** 53.0p9.0**** 53.7p7.7**** 50.4p11.8*** Acylcarnitine (nmol/ml) 13 Table 3 Scintigraphic data with BMIPP in normal subjects and patients with HCM H/M ratio, heart/mediastinum uptake ratio of BMIPP. Significance of differences : *P 0.005, **P 0.001, ***P 0.0001 compared with normal subjects.
Normal subjects (n l 20) HCM (n l 56) HNCM (n l 36) HOCM (n l 7) APH (n l 13) fatty acid metabolism. Quantitative analysis disclosed that the heart\mediastinum uptake ratio in HCM patients was significantly lower than that of normal subjects (2.11p0.12 and 2.33p0.16 respectively ; P 0.0001 ; Table 3 ). However, no statistically significant differences were seen among the HCM subtypes. In semi-quantitative analysis, normal subjects demonstrated no visually reduced BMIPP uptake in any segment of the myocardium, as shown in Figure 1 . The total defect score showed no statistically significant difference among HCM subtypes (Table 3) . Both quantitative and semiquantitative analyses demonstrated significant correlations with free carnitine levels (r l k0.422, P l 0.0012 and r l 0.633, P 0.0001 respectively) ( Figure 3) . Both of the analyses tended to correlate with acylcarnitine levels, although these correlations were not statistically significant (quantitative analysis : r l k0.251, P l 0.062 ; semi-quantitative analysis : r l 0.247, P l 0.066).
Characteristics of HCM patients showing high and normal free carnitine levels
To investigate the relationship between free carnitine levels and patient characteristics, patients with HCM were divided into two groups : 28 patients with high free carnitine levels (above meanj2 S.D. of the mean obtained from normal subjects) and 27 patients with normal free carnitine levels (within p2 S.D. of the mean). One patient with a low free carnitine level (below 2 S.D. of the mean) was excluded from this category. There were no significant differences in patient characteristics, such as clinical characteristics, echocardiographic findings or haemodynamic features, between the two groups, although there were significantly fewer female patients in the group with high free carnitine levels (P l 0.02 ; Table 4 ).
DISCUSSION
Kinetics of carnitine and fatty acid metabolism in patients with HCM
Carnitine is synthesized endogenously from lysine and methionine. In humans, the final reaction in carnitine synthesis, i.e. the hydroxylation of γ-butyrobetaine, occurs mainly in the liver, not in the heart [5] . The myocardial concentration of carnitine is about 80-140-fold higher than the plasma concentration [15] . Therefore carnitine uptake in the myocardium occurs against a large concentration gradient. A binding protein (carriermediated) [6, 23] , active transport [24] , diffusion [6] and an exchange system [25] have been proposed as the transport mechanism for carnitine. Approx. 90 % of the cellular carnitine is located in the cytoplasm, with the remaining 10 % in the mitochondria [26] . The present study has found that serum free carnitine concentrations were significantly higher, and acylcarnitine concentrations and acyl\free carnitine ratios were significantly lower, in patients with HCM than in normal subjects. These results suggest that, in HCM, carnitine is not adequately transported into the myocardium from the bloodstream, and β-oxidation subse-quently declines. York et al. [27] and Whitmer [28] investigated carnitine transport and myocardial metabolism using Bio 14.6 Syrian hamsters, representing a model for HCM. They reported that carnitine concentrations in the heart in Bio 14.6 Syrian hamsters were significantly lower throughout life, and plasma carnitine concentrations were higher from an early stage of life, compared with normal controls. These findings were observed before the hamsters began to show clinical symptoms of HCM and before severe histological pathology was evident. Furthermore, carnitine-binding protein, which is located on the surface of the plasma membrane, had a reduced maximal capacity for carnitine binding and an increased dissociation constant. Hoppel et al. [29] reported that the myocardial acylcarnitine\free carnitine ratio was not markedly affected in Bio 14.6 Syrian hamsters, although the levels of both free carnitine and acylcarnitine were markedly depressed. Mitochondrial enzymes, such as carnitine palmitoyltransferase and palmitoyl-and butyryl-CoA dehydrogenases, were unaffected, and myocardial total CoA levels were not depressed. These authors speculated that a ' steady-state ' ratio of carnitine to its metabolites is maintained, although they did not refer to the serum acylcarnitine\free carnitine ratio. If these findings are applicable to humans, the depressed serum acylcarnitine\ free carnitine ratio suggests that a disorder of the myocardial plasma membrane, affecting uptake of free carnitine into myocytes, is more closely related to the pathophysiology of HCM than mitochondrial damage. It is still unclear whether medium-and short-chain fatty acids substitute for long-chain fatty acids as substrates for β-oxidation in the affected myocardium of HCM patients. A positron-emission tomographic study using ")F-labelled 2-deoxyglucose showed enhanced myocardial glucose metabolism [30] , although a previous study reported depressed glucose metabolism [31] . Therefore it remains unclear whether glucose metabolism compensates for impaired myocardial fatty acid metabolism in HCM.
Patient characteristics demonstrated a statistically significant difference only with regard to the gender of patients with high and normal free carnitine concentrations. The amount of serum free carnitine in normal healthy volunteers has been reported to be greater in men than in women [19] , and this difference may have affected our results. The increase in plasma carnitine is reported to be more distinct in patients with a severely reduced leftventricular ejection fraction than in patients with a mildly reduced ejection fraction [10] . However, the ejection fraction was normal in all the HCM patients, and no statistically significant differences between the patients with high and normal free carnitine levels was observed. Inborn errors of fatty acid metabolism and carnitine deficiencies are reported to provoke secondary HCM, with low serum carnitine concentrations [32, 33] ; in contrast, our study revealed that the levels of free carnitine are increased in idiopathic HCM.
Kinetics of BMIPP and fatty acid metabolism in HCM patients
BMIPP is a radioiodinated long-chain-fatty-acid analogue used for the evaluation of cardiac fatty acid metabolism. A binding protein is considered to be associated with the transport of BMIPP from the bloodstream to the myocardium [34] . After injection, BMIPP is extracted extensively from the plasma into the myocardium (74 % of the injected dose), and is retained mainly in the triacylglycerol fraction (65.3 %). After washout from the myocardium, most of the retained radioactivity (8.7 %) is derived from metabolites of α-and β-oxidation [35] . Using etomoxir, an inhibitor of carnitine palmitoyltransferase I, Hosokawa et al. [36] investigated the metabolic fate of BMIPP. BMIPP was retained to a considerable extent in the myocardium, despite etomoxir treatment, but the amount of full metabolites of β-oxidation decreased significantly, and back-diffusion of BMIPP increased. These authors concluded that BMIPP is very sensitive to etomoxir and is suitable for assessing mitochondrial dysfunction [36] . In addition, a close positive correlation was shown between myocardial ATP content and BMIPP accumulation [37] . High serum levels of non-esterified fatty acids are reported to be associated with slow clearance of BMIPP from the myocardium [38] . However, none of our patients showed high levels of serum non-esterified fatty acids, so such an influence can be ruled out. The kinetics of BMIPP suggest that an impairment of the mitochondria and\or the plasma membrane may be related to the reduced or absent myocardial uptake of BMIPP in patients with HCM.
Reduced BMIPP uptake is seen in the hypertrophied myocardium, especially in the anterior and posterior junctions of the ventricular septum in HCM patients (see Figure 1 ). In addition, these segments correspond pathologically with myocardial disarray [39] . Maron et al. [40] investigated changes in the myocardium in HCM patients by electron microscopy. Operative biopsies in humans revealed mitochondrial damage, such as swelling of the mitochondria and disruption of the cristae, in 14 out of 15 patients. These abnormalities were more marked in the patients with a hypertrophied ventricular septum than in those with the left-ventricular free walls. In our institution, moreover, BMIPP myocardial scintigraphy and electron microscopic investigations were performed on WKY\NCrj rats, which are useful models for HCM [41] . BMIPP levels were reduced in the anterior and posterior junctions of the ventricular septum, and disruption of the mitochondrial cristae was prominent in the same region [42] . These results support our conclusions.
As shown in Figure 3 , serum free carnitine levels correlated significantly with depressed myocardial BMIPP uptake. Because myocardial BMIPP is indicative of fatty acid metabolism for the reasons described above, increased serum free carnitine levels indicate an impairment of myocardial fatty acid metabolism. In conclusion, high free carnitine concentrations and low acylcarnitine concentrations in serum indicate a significant impairment of myocardial fatty acid metabolism, which implies a disturbance in the plasma membrane and\or mitochondria in the hypertrophied myocardium in HCM patients. Also, serum free carnitine concentrations are increased even though the left-ventricular ejection fraction is normal, and they proved to be sensitive indicators for detecting impaired myocardial fatty acid metabolism even in the asymptomatic phase of HCM.
Study limitations
We did not investigate myocardial carnitine levels in this study. Myocardial carnitine levels have been shown to be significantly lower in HCM patients than in normal controls [27] [28] [29] . Transcatheter biopsy does not always obtain the affected myocardium, and approx. 70 % of the cellular carnitine is lost, even if the specimens are freshly prepared [43] . Thus the myocardial carnitine concentration is difficult to measure and seems to be somewhat unreliable ; instead, the serum carnitine concentration may adequately indicate myocardial fatty acid metabolism.
